<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158003">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816893</url>
  </required_header>
  <id_info>
    <org_study_id>2004P001233</org_study_id>
    <nct_id>NCT01816893</nct_id>
  </id_info>
  <brief_title>Hypoglycemia and Autonomic Nervous System Function</brief_title>
  <acronym>HypoANS</acronym>
  <official_title>Hypoglycemia and Autonomic Nervous System Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this proposal are to determine the effects of hypoglycemia on the autonomic
      nervous system and whether administration of a mineralocorticoid receptor antagonist
      modifies the effects of hypoglycemia on the autonomic nervous system
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Modified Oxford method assessment of baroreflex function</measure>
    <time_frame>1 day after euglycemic and hypoglycemic clamps</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle sympathetic nerve activity</measure>
    <time_frame>1 day after euglycemic and hypoglycemic clamps</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Catecholamine response to lower-body negative pressure</measure>
    <time_frame>1 day after euglycemic and hypoglycemic clamps</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Oxford method assessment of baroreflex function</measure>
    <time_frame>during euglycemic and hypoglycemic clamps</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Euglycemic clamp plus placebo.</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>participant undergoes a euglycemic hyperinsulinemic clamp with placebo pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypoglycemic clamp plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participant undergoes a hypoglycemic hyperinsulinemic clamp with placebo pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypoglycemia plus eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participant undergoes a hypoglycemic hyperinsulinemic clamp with eplerenone pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>hypoglycemia plus eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Euglycemic clamp plus placebo.</arm_group_label>
    <arm_group_label>hypoglycemic clamp plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Males and females age 18 to 50

          -  Type I Diabetes Mellitus, OR:

          -  Type II Diabetes Mellitus controlled by diet, exercise and oral glycemic control
             agents (metformin, thiazolidinediones, sulfonylureas)

        Exclusion Criteria:

          -  Hemoglobin A1c &gt; 9% (Type 2 Diabetes mellitus)

          -  Hemoglobin A1c &lt; 8% or &gt; 10% (Type 1 Diabetes mellitus)

          -  Pregnancy

          -  Lactation

          -  Recurrent hypoglycemic episodes within the past month

          -  Subjects who smoke will be required to refrain from smoking for the duration of each
             study admission

          -  Clinically significant coronary artery, cerebrovascular, or peripheral vascular
             disease, or presence of systemic illness that might affect autonomic function. Such
             illnesses include diabetes mellitus (controls only) congestive heart failure,
             hypertension (controls only), renal, pulmonary, hepatic disease, anemia,
             malignancies, untreated thyroid disease, and alchoholism.

          -  Current major depressive illness

          -  In both controls and diabetic subjects, any individuals on oral, injected, inhaled or
             topical corticosteroids within the last year or oral contraceptives within the past 3
             months will be excluded.

          -  Use of medications other than thyroxine in control subjects

          -  Use of medications other than thyroxine, metformin, thiazolidinediones,
             sulfonylureas, statins, ACE inhibitors, angiotensin receptor blockers (ARBs), and
             hydrochlorothiazide (HCTZ) in diabetic subjects

          -  Blood pressure &gt; 140/90 mmHg.

          -  Creatinine &gt; 1.5 mg/dL

          -  Serum potassium &gt;5.2 mmol/L

          -  Estimated GFR &lt; 50 mL/min
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail K Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy L Freeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Baimas-George, BA</last_name>
    <phone>617-525-7357</phone>
    <email>mbaimas-george@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Ballatori, BA</last_name>
    <phone>617-632-0648</phone>
    <email>sballato@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Baimas-George</last_name>
    </contact>
    <investigator>
      <last_name>Gail K Adler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ballatori</last_name>
    </contact>
    <investigator>
      <last_name>Roy Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care. 2008 Jun;31(6):1222-3. doi: 10.2337/dc07-2243. Epub 2008 Mar 10.</citation>
    <PMID>18332163</PMID>
  </results_reference>
  <results_reference>
    <citation>Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009 Feb;58(2):360-6. doi: 10.2337/db08-1153. Epub 2008 Dec 3.</citation>
    <PMID>19056608</PMID>
  </results_reference>
  <results_reference>
    <citation>Gibbons CH, Adler GK, Bonyhay I, Freeman R. Experimental hypoglycemia is a human model of stress-induced hyperalgesia. Pain. 2012 Nov;153(11):2204-9. doi: 10.1016/j.pain.2012.06.030. Epub 2012 Aug 23.</citation>
    <PMID>22921261</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 20, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gail Adler</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
